Core Insights - Firefly Neuroscience, Inc. reported significant financial growth in Q3-2025, with revenues increasing over tenfold year-over-year and 30% sequentially, primarily due to the acquisition of Evoke Neuroscience [4][7] - The company successfully integrated the Evoke business, leading to a 10.9% increase in EEG/ERP scan volumes quarter-over-quarter [3][7] - Operating expenses decreased by 35% year-over-year, contributing to a reduced net loss of $2.6 million, a 38% improvement compared to the same period in 2024 [5][6][7] Financial Performance - Q3-2025 revenue reached $388,000, up from $33,000 in Q3-2024, and a sequential increase from $299,000 in Q2-2025 [4][7] - Total operating expenses for Q3-2025 were approximately $2.8 million, down from $4.3 million in the prior year [5][7] - The net loss for Q3-2025 was approximately $2.6 million, or $0.20 per share, compared to a net loss of $4.3 million, or $0.61 per share, in Q3-2024 [6][7] Business Developments - The company is focused on executing its commercial growth strategy while leveraging NVIDIA's advanced software for developing EEG/ERP-based models of the human brain [3] - Firefly launched the 'CLEAR' platform for EEG data quality enhancement, developed using NVIDIA's L40S GPU [7] - A partnership with HealingMaps was established to provide cognitive electrophysiology analytics to over 2,500 clinics across North America [7] Cash Position - As of the end of Q3-2025, Firefly had cash reserves of $4.3 million [8]
Firefly Neuroscience Reports Third Quarter 2025 Financial Results